Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. Benjamin R, et al. Among authors: yallop d. Lancet Haematol. 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10. Lancet Haematol. 2022. PMID: 36228643 Clinical Trial.
Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription.
Buggins AG, Pepper C, Patten PE, Hewamana S, Gohil S, Moorhead J, Folarin N, Yallop D, Thomas NS, Mufti GJ, Fegan C, Devereux S. Buggins AG, et al. Among authors: yallop d. Cancer Res. 2010 Oct 1;70(19):7523-33. doi: 10.1158/0008-5472.CAN-10-1634. Epub 2010 Aug 24. Cancer Res. 2010. PMID: 20736369
Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma.
Noriega V, Kaur H, Devereux S, Byrne J, Marcus R, Haynes A, Yallop D, McMillan A, Ingram W, Khan A, Kenyon M, Potter V, Russell N, Mufti GJ, Pagliuca A. Noriega V, et al. Among authors: yallop d. Leuk Res. 2014 Jul;38(7):737-43. doi: 10.1016/j.leukres.2014.03.005. Epub 2014 Mar 18. Leuk Res. 2014. PMID: 24787231
Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.
Dhanapal V, Gunasekara M, Lianwea C, Marcus R, De Lord C, Bowcock S, Devereux S, Patten P, Yallop D, Wrench D, Fields P, Kassam S. Dhanapal V, et al. Among authors: yallop d. Leuk Lymphoma. 2017 Sep;58(9):1-9. doi: 10.1080/10428194.2016.1276288. Epub 2017 Jan 16. Leuk Lymphoma. 2017. PMID: 28093003
Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids.
Vidler J, Rogers C, Yallop D, Devereux S, Wellving E, Stewart O, Cox A, Hunt KF, Kassam S. Vidler J, et al. Among authors: yallop d. J Clin Transl Endocrinol. 2017 Jun 24;9:18-20. doi: 10.1016/j.jcte.2017.06.003. eCollection 2017 Sep. J Clin Transl Endocrinol. 2017. PMID: 29067264 Free PMC article.
27 results